Login / Signup
Mengdie Yuan
ORCID
Publication Activity (10 Years)
Years Active: 2023-2023
Publications (10 Years): 1
Top Topics
Drug Administration
Wild Type
Epidermal Growth Factor Receptor
Peritoneal Dialysis
Top Venues
Clinical cancer research : an official journal of the American Association for Cancer Research
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Sandra J Casak
,
M Naomi Horiba
,
Mengdie Yuan
,
Joyce Cheng
,
Steven J Lemery
,
Yuan Li Shen
,
Wentao Fu
,
Jason N Moore
,
Yangbing Li
,
Youwei Bi
,
Doris Auth
,
Nataliya Fesenko
,
Paul G Kluetz
,
Richard Pazdur
,
Lola A Fashoyin-Aje
FDA Approval Summary: Tucatinib with trastuzumab for advanced unresectable or metastatic, chemotherapy refractory, HER2 positive RAS wild type colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research
(2023)